Cargando…

A randomized controlled trial of Kundalini yoga in mild cognitive impairment

BACKGROUND: Global population aging will result in increasing rates of cognitive decline and dementia. Thus, effective, low-cost, and low side-effect interventions for the treatment and prevention of cognitive decline are urgently needed. Our study is the first to investigate the effects of Kundalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Eyre, Harris A., Siddarth, Prabha, Acevedo, Bianca, Van Dyk, Kathleen, Paholpak, Pattharee, Ercoli, Linda, St. Cyr, Natalie, Yang, Hongyu, Khalsa, Dharma S., Lavretsky, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540331/
https://www.ncbi.nlm.nih.gov/pubmed/28088925
http://dx.doi.org/10.1017/S1041610216002155
_version_ 1783254615338254336
author Eyre, Harris A.
Siddarth, Prabha
Acevedo, Bianca
Van Dyk, Kathleen
Paholpak, Pattharee
Ercoli, Linda
St. Cyr, Natalie
Yang, Hongyu
Khalsa, Dharma S.
Lavretsky, Helen
author_facet Eyre, Harris A.
Siddarth, Prabha
Acevedo, Bianca
Van Dyk, Kathleen
Paholpak, Pattharee
Ercoli, Linda
St. Cyr, Natalie
Yang, Hongyu
Khalsa, Dharma S.
Lavretsky, Helen
author_sort Eyre, Harris A.
collection PubMed
description BACKGROUND: Global population aging will result in increasing rates of cognitive decline and dementia. Thus, effective, low-cost, and low side-effect interventions for the treatment and prevention of cognitive decline are urgently needed. Our study is the first to investigate the effects of Kundalini yoga (KY) training on mild cognitive impairment (MCI). METHODS: Older participants (≥55 years of age) with MCI were randomized to either a 12-week KY intervention or memory enhancement training (MET; gold-standard, active control). Cognitive (i.e. memory and executive functioning) and mood (i.e. depression, apathy, and resilience) assessments were administered at baseline, 12 weeks and 24 weeks. RESULTS: At baseline, 81 participants had no significant baseline group differences in clinical or demographic characteristics. At 12 weeks and 24 weeks, both KY and MET groups showed significant improvement in memory; however, only KY showed significant improvement in executive functioning. Only the KY group showed significant improvement in depressive symptoms and resilience at week 12. CONCLUSION: KY group showed short- and long-term improvements in executive functioning as compared to MET, and broader effects on depressed mood and resilience. This observation should be confirmed in future clinical trials of yoga intervention for treatment and prevention of cognitive decline (NCT01983930).
format Online
Article
Text
id pubmed-5540331
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-55403312017-08-02 A randomized controlled trial of Kundalini yoga in mild cognitive impairment Eyre, Harris A. Siddarth, Prabha Acevedo, Bianca Van Dyk, Kathleen Paholpak, Pattharee Ercoli, Linda St. Cyr, Natalie Yang, Hongyu Khalsa, Dharma S. Lavretsky, Helen Int Psychogeriatr 2016 IPA Junior Research Awards – Second Prize Winner BACKGROUND: Global population aging will result in increasing rates of cognitive decline and dementia. Thus, effective, low-cost, and low side-effect interventions for the treatment and prevention of cognitive decline are urgently needed. Our study is the first to investigate the effects of Kundalini yoga (KY) training on mild cognitive impairment (MCI). METHODS: Older participants (≥55 years of age) with MCI were randomized to either a 12-week KY intervention or memory enhancement training (MET; gold-standard, active control). Cognitive (i.e. memory and executive functioning) and mood (i.e. depression, apathy, and resilience) assessments were administered at baseline, 12 weeks and 24 weeks. RESULTS: At baseline, 81 participants had no significant baseline group differences in clinical or demographic characteristics. At 12 weeks and 24 weeks, both KY and MET groups showed significant improvement in memory; however, only KY showed significant improvement in executive functioning. Only the KY group showed significant improvement in depressive symptoms and resilience at week 12. CONCLUSION: KY group showed short- and long-term improvements in executive functioning as compared to MET, and broader effects on depressed mood and resilience. This observation should be confirmed in future clinical trials of yoga intervention for treatment and prevention of cognitive decline (NCT01983930). Cambridge University Press 2017-04 2017-01-16 /pmc/articles/PMC5540331/ /pubmed/28088925 http://dx.doi.org/10.1017/S1041610216002155 Text en © International Psychogeriatric Association 2017 http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 2016 IPA Junior Research Awards – Second Prize Winner
Eyre, Harris A.
Siddarth, Prabha
Acevedo, Bianca
Van Dyk, Kathleen
Paholpak, Pattharee
Ercoli, Linda
St. Cyr, Natalie
Yang, Hongyu
Khalsa, Dharma S.
Lavretsky, Helen
A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title_full A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title_fullStr A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title_full_unstemmed A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title_short A randomized controlled trial of Kundalini yoga in mild cognitive impairment
title_sort randomized controlled trial of kundalini yoga in mild cognitive impairment
topic 2016 IPA Junior Research Awards – Second Prize Winner
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540331/
https://www.ncbi.nlm.nih.gov/pubmed/28088925
http://dx.doi.org/10.1017/S1041610216002155
work_keys_str_mv AT eyreharrisa arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT siddarthprabha arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT acevedobianca arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT vandykkathleen arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT paholpakpattharee arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT ercolilinda arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT stcyrnatalie arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT yanghongyu arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT khalsadharmas arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT lavretskyhelen arandomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT eyreharrisa randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT siddarthprabha randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT acevedobianca randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT vandykkathleen randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT paholpakpattharee randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT ercolilinda randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT stcyrnatalie randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT yanghongyu randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT khalsadharmas randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment
AT lavretskyhelen randomizedcontrolledtrialofkundaliniyogainmildcognitiveimpairment